Balance Sheet
Cash Flow Statement
AmortizationAmortizationAmortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in Working CapitalChange in Working CapitalDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Cash from Financing Activities (2019 - 2025)

Legend Biotech filings provide 7 years of Cash from Financing Activities readings, the most recent being -$600000.0 for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities fell 100.0% to -$600000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$253000.0, a 104.41% decrease, with the full-year FY2025 number at -$300000.0, down 105.26% from a year prior.
  • Cash from Financing Activities hit -$600000.0 in Q4 2025 for Legend Biotech, down from $670000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $790.0 million in Q2 2023 to a low of -$990000.0 in Q2 2025.
  • Median Cash from Financing Activities over the past 5 years was $878000.0 (2023), compared with a mean of $90.1 million.
  • The widest YoY moves for Cash from Financing Activities: up 78200.1% in 2023, down 1876.0% in 2023.
  • Legend Biotech's Cash from Financing Activities stood at $323.6 million in 2021, then plummeted by 100.24% to -$783000.0 in 2022, then skyrocketed by 218.14% to $925000.0 in 2023, then plummeted by 132.43% to -$300000.0 in 2024, then plummeted by 100.0% to -$600000.0 in 2025.
  • The last three reported values for Cash from Financing Activities were -$600000.0 (Q4 2025), $670000.0 (Q3 2025), and -$990000.0 (Q2 2025) per Business Quant data.